Patrick I. Eacho

TL;DR: Angptl3 and Angptl4 function to regulate circulating triglyceride levels during different nutritional states and therefore play a role in lipid metabolism during feeding/fasting through differential inhibition of LPL.

TL;DR: It is shown that the regulation of the liver gluconeogenic pathway by LXR agonists was a direct effect on hepatocytes, and an unanticipated role for these receptors is revealed, further linking lipid and glucose metabolism.

TL;DR: Results reveal that secreted PCSK9 retains biological activity, is able to bind directly to the LDLR extracellular domain, and undergoes LDLR-ARH-mediated endocytosis, leading to accelerated intracellular degradation of the HDLR.

TL;DR: It is concluded that PLTP is a direct target gene of LXRs in vivo and plays an important role in LXR agonist-mediated HDL cholesterol and size increase in mice.

TL;DR: Evidence is provided that small molecule LXR/RXR agonists can effectively mediate apoE synthesis and secretion as well as cholesterol homeostasis in astrocytes and treatment of mice with a specific synthetic LXR agonist resulted in up‐regulation of ApoE mRNA and protein in both hippocampus and cerebral cortex.